Linganisha mbinu

	Maswali ya Tathmini ya Athari za Upotevu wa Nywele (ALPPQ)	Skindex-29 (Kipimo cha Ubora wa Maisha wa Magonjwa ya Ngozi)
Nyanja	Dermatolojia	Dermatolojia
Familia	Process / pipeline	Process / pipeline
Mwaka wa asili	2014	1997
Mwanzilishi	Gupta AK, Strober BE et al.	Chren MM, Lasek RJ
Aina	Self-report	Self-report
Chanzo asilia	Gupta AK, Talukder M. Alopecia areata: autoimmune basis of hair loss and available treatment options. Can J Dermatol. 2014;12(5):289-304.	Chren MM, Lasek RJ, Quinn LM, et al. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1997;107(5):707-713.
Majina mbadala	Hair Loss Impact Questionnaire, Alopecia Areata QoL	Skindex, Skindex-QoL
Zinazohusiana	4	1
Muhtasari	The Hair Loss Impact Questionnaire (Alopecia Areata Patient Priority Outcomes Questionnaire, ALPPQ) is a disease-specific, patient-administered quality-of-life measure assessing the psychosocial and functional burden of alopecia areata, a chronic autoimmune disorder causing patchy hair loss. Alopecia areata affects appearance, self-esteem, and social functioning disproportionately, often causing depression and anxiety. The ALPPQ captures these impacts, ensuring that treatment efficacy encompasses meaningful quality-of-life outcomes. It is increasingly used in clinical trials and observational studies of alopecia areata therapeutics.	Skindex-29 is a validated, patient-centered quality-of-life measure specifically designed to assess the impact of any skin disease on patients' symptoms, emotions, and functioning. Developed by Chren, Lasek, and colleagues in 1997, it captures the multidimensional burden of dermatological conditions beyond clinical severity. Skindex-29 is widely used in clinical trials, observational studies, and dermatology practice to ensure that treatment efficacy encompasses quality-of-life outcomes.